DROSPIRENONE-BASED CONTRACEPTIVE FOR AN OVERWEIGHT PATIENT

MA42233AActive Publication Date: 2018-05-02LAB LEON FARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MA42233
Authority / Receiving Office
MA · MA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-06-23
Filing Date
2016-06-23
Publication Date
2018-05-02
Estimated Expiration
2036-06-23

AI Technical Summary

Technical Problem

Hormonal contraceptives, particularly combined oral contraceptives, pose a heightened risk of venous thromboembolism in obese women, and progestin-only contraceptives often result in bleeding irregularities and weight gain, leading to discontinuation and increased risk of unintended pregnancy in women with excess weight.

Method used

A drospirenone-based contraceptive formulation with a daily active dosage unit of at least 3 mg, administered in a 28-day regimen, which reduces the number of bleeding events and allows for flexible dosing, providing a pharmacokinetic profile that minimizes venous thromboembolism risk and bleeding irregularities while potentially aiding in weight management.

Benefits of technology

The drospirenone-based contraceptive significantly reduces the number of bleeding events in overweight and obese women, enhances compliance by minimizing bleeding issues, and may contribute to weight loss, thereby reducing the risk of unintended pregnancy and associated health complications.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Drospirenone as the sole contraceptive ingredient comprised in a daily active dosage unit in an amount of at least 3 mg for use as a contraceptive for a female patient affected with obesity.
Need to check novelty before this filing date? Find Prior Art